Ventricular Tachycardia
245
36
45
109
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
42 trials with published results (17%)
Research Maturity
109 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.4%
23 terminated out of 245 trials
82.6%
-3.9% vs benchmark
10%
25 trials in Phase 3/4
39%
42 of 109 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 109 completed trials
Clinical Trials (245)
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies
Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention
Mayo AVC Registry and Biobank
Randomized Assessment of TcMS for VT Storm
Cardiac Radioablation for VT
Power Versus Temperature Controlled Ablation for Treatment of VT
VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation
CHU Dual-Energy Ablation in Ventricular Arrhythmia
Venous Ethanol for Ventricular Tachycardia
Coronary Flow During Rapid Heart Rates
DEEP Substrate Mapping Versus Activation Mapping for VT
Functional Substrate-Only Guided VT Ablation
Pediatric Lead Extractability and Survival Evaluation (PLEASE)
Cohort Study - SBRT for VT Radioablation
Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Improving Patient Reported Outcome Measures in Catheter Ablation